Kaitai Capital is a Hangzhou based venture capital management company investing in innovative technology companies in multiple industries world wide. Kaitai focuses its investments on biotechnology, medicine, healthcare services, agriculture tech, consumer business, outdoor sports, financial services, artificial intelligence, and digital technology. Founded in 2009, it has physical presence in San Jose, United States, and Hangzhou and Beijing in China. As of 2019, the company has invested in 28 companies with two successful exits.
A clinical-stage biopharmaceutical company engaging in drug discovery and drug development for treating autoimmune disease and cancer.
Amphivena Therapeutics is a San Francisco-based company.